Cargando…
Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
Background: Long-acting injectable (LAI) aripiprazole was found to be efficacious in schizophrenia. In common clinical practice, the use of LAIs is often restricted to chronic patients with frequent relapses and poor adherence. Recently, some investigators advanced the idea of early LAI use also in...
Autores principales: | Giordano, Gloria, Tomassini, Lorenzo, Cuomo, Ilaria, Amici, Emanuela, Perrini, Filippo, Callovini, Gemma, Carannante, Alfonso, Kotzalidis, Georgios D., De Filippis, Sergio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960223/ https://www.ncbi.nlm.nih.gov/pubmed/31969843 http://dx.doi.org/10.3389/fpsyt.2019.00935 |
Ejemplares similares
-
Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo, Ilaria, et al.
Publicado: (2018) -
Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder
por: Kotzalidis, Georgios D., et al.
Publicado: (2021) -
Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma
por: De Filippis, Sergio, et al.
Publicado: (2022) -
Clinical stabilisation with lacosamide of mood disorder comorbid with PTSD and fronto-temporal epilepsy
por: Cuomo, Ilaria, et al.
Publicado: (2017) -
P.0669 Differential response to three antidepressants in patients with major depressive episode who suffered Covid-19–related trauma
por: Lombardozzi, G., et al.
Publicado: (2021)